Amgen earnings top analyst forecasts
Amgen Inc. on Tuesday reported first-quarter net income of $1.62 billion.
On a per-share basis, the Thousand Oaks-based company said it had net income of $2.11. Earnings, adjusted for costs related to mergers and acquisitions, were $2.48 per share.
The results exceeded Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $2.07 per share.
The world’s largest biotech drugmaker posted revenue of $5.03 billion in the period, also beating Street forecasts. Snalysts surveyed by Zacks expected $4.92 billion.
Amgen expects full-year earnings in the range of $9.35 to $9.65 per share, with revenue in the range of $20.9 billion to $21.3 billion.
Amgen shares have climbed almost 6 percent since the beginning of the year, while the Standard & Poor’s 500 index has climbed nearly 2 percent. In the final minutes of trading on Tuesday, shares hit $168.46, an increase of 44 percent in the last 12 months.
Your guide to our clean energy future
Get our Boiling Point newsletter for the latest on the power sector, water wars and more — and what they mean for California.
You may occasionally receive promotional content from the Los Angeles Times.
More From the Los Angeles Times
-
Stocks are mostly falling in early trading on Wall Street on Tuesday as CEOs of the biggest banks paint a mixed picture of the coronavirus’ effects.
-
U.S. consumer prices posted the biggest monthly gain since 2012 on a rebound in gasoline costs, though inflation remained subdued more broadly amid the pandemic.
-
Britain backtracks on plans to give Huawei a role in its 5G mobile phone network, a decision that will please President Trump but anger China.
-
Some real estate investors specialize in combing public records for homes in desirable areas and making lowball offers for “off-market” purchases.
